Maintaining the Cold Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Maintaining the Cold Chain


Pharmaceutical Technology



Hallie Forcinio
Drugs shipped by truck, train, ship, or aircraft can be subjected to temperatures ranging from far below zero to well above 100 F, sometimes during the same trip. Exposure to these extremes can be disastrous for temperature-sensitive products. In less severe cases, shelf life can be shortened. In worst-case scenarios, product can be ruined, resulting in losses that can add up to hundreds of thousands of dollars.

To help pharmaceutical manufacturers protect temperature-sensitive products during shipment, the Parenteral Drug Association (Bethesda, MD, http://www.pda.org/) has published a guidance document drafted by its Cold Chain Management Task Force and reviewed by technical experts from the industry. Several years in the making, "Technical Report No. 39: Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment" discusses how to develop protective packages and systems to provide "thermally controlled transportation" (1). The guidance also aligns with the Center for Drug Evaluation and Research's (Bethesda, MD, http://www.fda.gov/) "General Principles of Process Validation: Component Qualification (CQ), Operating Qualification (OQ), and Performance Qualification (PQ)."


Multiple layers of CrioMED Plus insulated bag protect product inside from temperature extremes.
Stability studies. Determining how to protect products depends heavily on stability studies. Actual studies are needed because "Long-term storage or label storage temperatures may be different from short-term shipping/distribution temperatures" (1). Three types of studies should be undertaken to address temperature control issues: long-term, accelerated, and temperature excursion. Temperature excursion studies are particularly important because it's not uncommon for shipments to be exposed to conditions outside anticipated extremes because of weather, delays, equipment malfunctions, mishandling, or other causes.

All levels of packaging from primary container–closures to distribution packaging affect the product's thermal stability and should be included in the testing program. In fact, "The more empty space within the secondary package not utilized by the thermal mass of the product, the more difficult it is to control the system thermally" (1).

Developing a protective system. The development of a thermally protective system begins with the creation of a functional requirements document and the specification of components such as insulated containers and refrigerants. The functional requirements document includes the critical parameters related to the packaging and transport systems such as the types of vehicle, routes, trip duration, product stability, likely temperature range of exposure, and packaging. The component specification is a detailed description of requirements for features such as material composition, mechanical characteristics, dimensions, printing, storage, sampling, weight, insulation, calibration limits, fragility limits, and shock and vibration limits.

Design testing is the next step. "The outcome of design testing assures a high confidence for successful operational qualification of a specific package or system," the report explains (1).

Then, qualification testing is "performed using the designated configuration to provide assurance that product quality is maintained during transport." Both design and qualification testing results should be documented in a formal report (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here